List of Excipients in Branded Drug CHILDRENS ROBITUSSIN 12 HOUR COUGH RELIEF

Generic Drugs Containing CHILDRENS ROBITUSSIN 12 HOUR COUGH RELIEF

Company	Ingredient	NDC	Excipient
Haleon US Holdings LLC	dextromethorphan polistirex	0031-8725	D&C RED NO. 30
Haleon US Holdings LLC	dextromethorphan polistirex	0031-8725	D&C YELLOW NO. 10
Haleon US Holdings LLC	dextromethorphan polistirex	0031-8725	GLYCERIN

What are the Most Frequently-Used Excipients in CHILDRENS ROBITUSSIN 12 HOUR COUGH RELIEF?

# Of NDCs	Excipient
1	D&C RED NO. 30
1	D&C YELLOW NO. 10
1	GLYCERIN

Children's Robitussin 12 Hour Cough Relief: Excipient Strategy, Formulation Economics, and Commercial Opportunities

Last updated: September 9, 2026

Children's Robitussin 12 Hour Cough Relief is an extended-release oral suspension built around dextromethorphan polistirex, an ion-exchange resin complex that releases dextromethorphan over approximately 12 hours. Its commercial value comes from dosing convenience, pediatric positioning, brand recognition, and the technical difficulty of reproducing acceptable taste, viscosity, dose uniformity, and release performance in a liquid product.

The principal commercial opportunity is not a new chemical entity. It is an improved pediatric extended-release suspension with better palatability, lower sugar content, cleaner excipient labeling, stronger dose-delivery controls, and a differentiated package or delivery device.

What active ingredient is used in Children's Robitussin 12 Hour Cough Relief?

Children's Robitussin 12 Hour Cough Relief uses dextromethorphan polistirex as the active pharmaceutical ingredient. Dextromethorphan polistirex is a polymeric or resin-bound form of dextromethorphan designed to provide prolonged release after oral administration.

The labeled strength is commonly expressed as an equivalent amount of dextromethorphan hydrobromide. Product labeling for extended-release pediatric cough suspensions generally identifies 30 mg dextromethorphan hydrobromide equivalent per 5 mL, although the exact marketed presentation and label should be confirmed against the applicable package and regulatory record.[1]

Attribute	Product profile
Brand	Children's Robitussin 12 Hour Cough Relief
Therapeutic category	OTC antitussive
Active ingredient	Dextromethorphan polistirex
Dosage form	Oral extended-release suspension
Release period	Approximately 12 hours
Primary users	Pediatric consumers within labeled age ranges
Regulatory pathway	OTC drug labeling and monograph framework
Principal technical risks	Sedimentation, dose nonuniformity, taste, viscosity, resin release control

Dextromethorphan is subject to the FDA's OTC cough and cold framework, including age-related labeling and safety requirements. The product is not an antibiotic, biologic, controlled-release tablet, or prescription extended-release medicine.

What excipients are used in the product?

The excipient system is designed to suspend the resin complex, maintain dose uniformity, control viscosity, preserve the product, buffer the formulation, and improve pediatric acceptability.

Publicly available product labeling for dextromethorphan polistirex suspensions identifies excipient classes that can include the following:

Excipient class	Typical function in the formulation
Sucrose or other sweetener	Palatability and mouthfeel
Glycerin	Humectant, solvent, sweetness, mouthfeel
Xanthan gum	Suspending and viscosity agent
Microcrystalline cellulose and carboxymethylcellulose sodium	Structured suspension vehicle
Ethylcellulose	Resin or particle coating and release-control support
Citric acid and sodium citrate	pH adjustment and buffer capacity
Edetate disodium	Chelation and stability support
Methylparaben or another preservative	Microbial protection
Flavor system	Pediatric taste masking
Colorant	Product identification and consumer acceptance

The exact inactive ingredient list can differ by manufacturer, strength, market, or manufacturing site. DailyMed and the current package insert are the controlling sources for a specific stock-keeping unit.[1]

Why the suspension system matters

Dextromethorphan polistirex is not simply dissolved in water. The resin complex must remain evenly distributed during storage and use. The formulation therefore needs enough yield stress to limit settling while remaining pourable and easy to measure.

A poorly balanced suspension can create two commercial and regulatory problems:

1. The first doses may contain less active ingredient than the last doses.
2. The product may become difficult for a child or caregiver to pour, shake, or measure.

Xanthan gum and microcrystalline cellulose-carboxymethylcellulose systems are widely used because they can generate pseudoplastic flow. The suspension is relatively thick at rest but becomes less viscous when shaken or poured. This behavior supports both physical stability and consumer handling.

How does the excipient system control extended release?

The principal release-control mechanism is associated with the dextromethorphan-resin complex rather than with the external syrup vehicle alone. The resin binds the active ingredient and allows exchange processes in gastrointestinal fluids to release dextromethorphan over time.

Excipients still affect the product's performance. Relevant variables include:

• particle-size distribution of the resin complex;
• polymer coating or barrier characteristics;
• pH and ionic strength;
• viscosity of the liquid vehicle;
• wetting and dispersion behavior;
• preservative concentration;
• agitation before dosing;
• container closure and storage conditions.

A reformulator cannot assume that a change in sweetener, buffer, gum, or flavor is clinically irrelevant. Changes can alter wetting, settling, resin hydration, dose withdrawal, and in-vitro release.

For a generic or private-label product, the central development challenge is demonstrating pharmaceutical equivalence and bioequivalence or satisfying the applicable OTC regulatory pathway. A product that matches the labeled milligrams per 5 mL but fails to match release characteristics can face regulatory and commercial barriers.

What are the most important pediatric excipient risks?

Pediatric cough products require a narrower excipient risk tolerance than adult liquid medicines because taste, dose measurement, allergy concerns, and caregiver error directly affect use.

Sugar load

Sucrose supports palatability and viscosity, but it creates commercial pressure from parents seeking lower-sugar products. Sugar-free versions can use sorbitol, maltitol, glycerin, sucralose, acesulfame potassium, or combinations of these ingredients.

Sugar alcohols can cause gastrointestinal discomfort at sufficiently high exposure. The formulation must balance sweetness against laxative potential, osmolality, and aftertaste.

Preservatives

Parabens are effective and familiar preservatives, but some consumers and retailers prefer preservative-free products. Removing a preservative requires a validated alternative preservation strategy, stronger microbiological controls, or a packaging system that limits contamination.

Potential alternatives include potassium sorbate, sodium benzoate, or benzoic acid, depending on pH and formulation compatibility. Preservative selection must account for pediatric exposure, flavor impact, container interaction, and preservative efficacy testing under USP <51> or the applicable standard.[2]

Colorants

Colorants help distinguish products and strengthen brand recognition. They also create avoidable consumer objections in "clean label" and pediatric wellness channels. A no-artificial-color version could support premium positioning, but it may have a less distinctive appearance and greater risk of perceived instability.

Flavor and taste masking

Taste masking is a primary commercial differentiator. Dextromethorphan can produce bitterness, medicinal notes, and lingering aftertaste. Resin binding may reduce immediate taste exposure, but the formulation still needs a flavor system that handles both the active complex and the excipient base.

Fruit flavors such as grape, cherry, berry, or orange are common in pediatric medicines. The strongest opportunity may be a flavor architecture with:

• rapid sweetness on first contact;
• suppression of bitter and resinous notes;
• low lingering aftertaste;
• limited flavor volatility;
• acceptable performance after storage.

Flavor optimization should use pediatric sensory methods where permitted, with adult caregiver panels for acceptability and child-appropriate methods for preference testing.

Alcohol and propylene glycol

A pediatric formulation can gain positioning value by avoiding ethanol and minimizing propylene glycol. Even where permitted, these ingredients may generate retailer or caregiver resistance. Their removal can affect solubility, flavor delivery, preservative performance, and viscosity.

What formulation patents protect extended-release dextromethorphan suspensions?

The commercial protection for a legacy OTC product is more likely to depend on formulation know-how, trademarks, regulatory data, manufacturing controls, and trade secrets than on a currently enforceable composition patent.

Potentially protectable technical features include:

• a specific dextromethorphan-resin complex;
• polymer or ethylcellulose coating parameters;
• defined particle-size ranges;
• a suspension vehicle with specified rheological properties;
• a low-sugar or sugar-free formulation;
• improved dose uniformity after storage;
• a flavor-masking system;
• a package and dosing-device combination;
• a preservative-free multidose container;
• a manufacturing process that reduces agglomeration.

Because the product is an OTC medicine rather than a conventional prescription NDA product, it should not be assumed that an Orange Book-listed patent estate exists. Orange Book listing depends on the applicable regulatory application and patent certification framework. A product-level freedom-to-operate analysis requires the exact applicant, National Drug Code, current label, and relevant patent families.

What is the FDA regulatory status of Children's Robitussin 12 Hour Cough Relief?

Dextromethorphan is recognized in the FDA's OTC cough and cold regulatory framework. The relevant rules address active ingredients, indications, warnings, directions, and labeling requirements for cough and cold products.[3]

Key regulatory issues include:

Regulatory issue	Commercial effect
Pediatric age restrictions	Limits target population and marketing claims
Dextromethorphan misuse concerns	Requires careful consumer education and packaging
Measuring-device accuracy	Affects dose compliance and product liability
Shake-well instructions	Critical for suspension uniformity
Tamper-evident packaging	Required for consumer confidence and compliance
Stability and microbiological control	Determines shelf life and manufacturing cost
Flavor and color claims	Must remain consistent with labeling and advertising rules

FDA has advised against use of OTC cough and cold medicines in children younger than four years and has supported manufacturer labeling changes for young children.[4] Commercial messaging must not extend beyond the approved or monograph-supported population.

When does Children's Robitussin lose exclusivity?

A single exclusivity date is generally not available for this type of OTC product. The product's market protection may arise from several overlapping sources:

1. Brand trademark rights.
2. Trade dress and packaging.
3. Manufacturing know-how.
4. Private-label supply agreements.
5. Product-specific regulatory history.
6. Any surviving patent claims.
7. Retail distribution and consumer recognition.

A legacy OTC product can face competing products even when the branded formulation remains commercially successful. Generic or store-brand products may enter through an OTC monograph route without a conventional Paragraph IV challenge to an Orange Book patent.

Are there Paragraph IV challenges for this product?

A conventional Paragraph IV litigation pathway is not the primary expected challenge route for a monograph-based OTC pediatric cough suspension. Paragraph IV certifications apply principally to abbreviated applications referencing listed drugs and Orange Book patents.

For Children's Robitussin 12 Hour Cough Relief, competitive entry is more likely to occur through:

• an OTC monograph-compliant product;
• a private-label product supplied by a contract manufacturer;
• an equivalent dextromethorphan extended-release suspension;
• a reformulated product with a different excipient profile;
• a store-brand product using similar resin-release technology.

The absence of a visible Paragraph IV dispute does not eliminate commercial risk. It shifts the risk from patent litigation toward formulation replication, regulatory compliance, retailer access, and supply economics.

Which companies are challenging the product commercially?

The competitive set includes branded and private-label manufacturers selling dextromethorphan products, including:

• Reckitt and its Robitussin portfolio;
• Perrigo;
• CVS, Walgreens, Walmart, Target, and other store-brand programs;
• contract manufacturers producing OTC cough products;
• manufacturers of extended-release dextromethorphan liquids and alternative dosage forms.

Immediate-release syrups, capsules, dissolving strips, lozenges, and combination cough products compete with a 12-hour suspension even when they do not directly duplicate the formulation.

The most direct competitors are products that offer the same active ingredient, pediatric labeling, and extended-duration dosing. The largest indirect competitors are low-cost immediate-release products and non-drug cough remedies marketed around convenience or perceived safety.

What commercial opportunities exist for excipient reformulation?

1. Sugar-free extended-release suspension

A sugar-free formulation can target parents managing dental health, diabetes-related concerns, or broader "better-for-you" preferences. The key development risks are aftertaste, laxation, viscosity, and preservative compatibility.

2. Clean-label pediatric product

A product without artificial color, without parabens, and with a simplified excipient statement could support premium pricing. The commercial case depends on preserving taste and stability without creating a materially higher cost of goods.

3. Better dosing device

A calibrated oral syringe or high-accuracy dosing cup can reduce caregiver error. A package combining a bottle adaptor with a syringe could differentiate the product more effectively than a minor flavor change.

4. Smaller, portable package

A single-dose or travel-size presentation could serve households seeking convenience, schools operating under medication policies, and travel retail. Unit-dose packaging raises packaging cost and waste but improves hygiene and dose control.

5. Pediatric flavor platform

A proprietary flavor system that reduces bitterness and aftertaste could be licensed across cough, cold, allergy, and analgesic products. The asset would have broader value than a single Robitussin-style product.

6. Sustainable packaging

Recyclable resin, reduced plastic, and lower-packaging-volume options may appeal to major retailers. The package must preserve moisture protection, child resistance where applicable, tamper evidence, and suspension stability.

How strong is the patent estate for this product?

The likely patent estate is moderate to weak for a direct legacy-product copy unless a specific surviving patent covers the resin complex, release profile, formulation, or manufacturing process. The stronger barriers are technical execution and retail economics.

Protection category	Likely strength
Active ingredient	Low; dextromethorphan is established
Basic pediatric syrup	Low
Extended-release resin complex	Moderate, depending on claim scope and expiration
Specific suspension rheology	Moderate if supported by valid claims
Flavor system	Low to moderate
Dosing package	Moderate for narrow device claims
Trademark and trade dress	Strong for brand recognition, not formulation exclusivity
Manufacturing know-how	Potentially strong if difficult to reproduce

A competitor with a technically competent contract manufacturer may reproduce the core product concept. A competitor may still fail commercially if it cannot deliver stable suspension behavior, acceptable taste, regulatory-compliant labeling, and reliable retail supply.

What manufacturing and IP barriers affect generic launch?

The main barriers are process and quality controls:

• consistent production of the resin-bound active;
• control of particle size and agglomeration;
• uniform dispersion at commercial scale;
• reproducible viscosity across batches;
• adequate microbial preservation;
• release testing that correlates with in-vivo performance;
• compatibility with bottle, cap, liner, and dosing device;
• stability after repeated opening;
• accurate fill volume and label claim.

A generic launch strategy should prioritize a formulation that is robust to ordinary caregiver handling. The product must remain pourable after storage, redisperse after shaking, and provide consistent dosing through the final bottle volume.

How does Children's Robitussin compare with immediate-release dextromethorphan products?

Factor	12-hour suspension	Immediate-release product
Dosing frequency	Lower	Higher
Formulation complexity	High	Moderate
Taste-masking burden	High	High
Suspension risk	High	Low or absent in solid forms
Pediatric convenience	Strong	Moderate
Manufacturing cost	Higher	Lower in tablets or capsules
Differentiation potential	High	Limited
Generic substitution pressure	Moderate	High
Device importance	High	Low for solid dosage forms

The 12-hour format has a clear convenience advantage, but it carries higher technical and quality costs. A successful competitor should not compete only on price. It should use a defined advantage in taste, sugar content, dosing accuracy, package size, or retailer positioning.

What revenue exposure and launch scenarios are most relevant?

Revenue exposure is concentrated in the branded pediatric cough segment and is sensitive to seasonality, retailer inventory, respiratory illness trends, and public scrutiny of pediatric cough medicines.

Three launch scenarios are commercially relevant:

Low-cost private-label launch

The manufacturer matches the active ingredient and broad dosage form, then competes on price. This is the fastest route but faces limited differentiation and potential retailer margin pressure.

Premium reformulation launch

The product uses a sugar-free, no-artificial-color, improved-flavor, or enhanced-device proposition. This strategy supports higher pricing but requires stronger clinical, stability, sensory, and regulatory substantiation.

Platform licensing

A company licenses the resin-release technology, flavor system, or suspension vehicle to multiple OTC manufacturers. This can produce broader revenue than launching a single branded product, but it requires defensible know-how and consistent manufacturing transfer.

Key Takeaways

• Children's Robitussin 12 Hour Cough Relief is an extended-release dextromethorphan polistirex suspension.
• Its excipient system controls suspension stability, taste, viscosity, preservation, and dose uniformity.
• The strongest reformulation opportunities are sugar-free delivery, reduced artificial ingredients, improved flavor, and better dosing devices.
• The product is more likely to face OTC monograph and private-label competition than a conventional Paragraph IV patent challenge.
• The core active ingredient has limited exclusivity value; manufacturing know-how, brand recognition, packaging, and retail access provide the more important commercial defenses.
• A generic or private-label entrant must reproduce not only the labeled strength but also acceptable release, suspendability, taste, microbiological quality, and dose delivery.
• A differentiated excipient platform could support licensing across multiple pediatric OTC categories.

FAQs

Can dextromethorphan polistirex be formulated without sugar?

Yes. Sugar-free versions are technically feasible, but the developer must manage sweetness, aftertaste, viscosity, osmolality, preservative performance, and gastrointestinal tolerance.

Is dextromethorphan polistirex the same as dextromethorphan hydrobromide?

No. Dextromethorphan polistirex is a resin-bound extended-release form. Label strengths are commonly expressed as dextromethorphan hydrobromide equivalents.

Does a change in flavor require a new drug application?

Not necessarily. The regulatory consequence depends on the product's legal pathway, the nature of the change, the applicable OTC framework, and whether the change affects safety, quality, performance, or labeling.

What is the most defensible formulation improvement?

A formulation improvement combining reliable extended release, superior pediatric taste, and accurate dosing has greater commercial value than a single excipient substitution.

Can a store brand copy the Children's Robitussin formulation?

A store brand may develop a competing dextromethorphan extended-release suspension if it satisfies the applicable regulatory requirements and avoids enforceable patent, trademark, trade dress, and proprietary manufacturing claims.

References

1. U.S. National Library of Medicine. (n.d.). DailyMed: Dextromethorphan polistirex extended-release oral suspension labeling. https://dailymed.nlm.nih.gov/
2. United States Pharmacopeia. (2024). USP-NF general chapter <51>: Antimicrobial effectiveness testing. United States Pharmacopeial Convention.
3. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. https://www.ecfr.gov/
4. U.S. Food and Drug Administration. (2008). FDA recommends that consumers not give over-the-counter cough and cold medicines to children under 2. https://www.fda.gov/